ArticleFrontiers in public health2024

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China.

Xiaoyu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.